CA2579884C - Procede pour traiter les saignements locaux tracheaux, bronchiques ou alveolaires ou l'hemoptysie - Google Patents

Procede pour traiter les saignements locaux tracheaux, bronchiques ou alveolaires ou l'hemoptysie Download PDF

Info

Publication number
CA2579884C
CA2579884C CA2579884A CA2579884A CA2579884C CA 2579884 C CA2579884 C CA 2579884C CA 2579884 A CA2579884 A CA 2579884A CA 2579884 A CA2579884 A CA 2579884A CA 2579884 C CA2579884 C CA 2579884C
Authority
CA
Canada
Prior art keywords
fviia
use according
variant
bleeding
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2579884A
Other languages
English (en)
Other versions
CA2579884A1 (fr
Inventor
Lars Heslet
Lars Otto Uttenthal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaorigin AS
Original Assignee
Pharmaorigin AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaorigin AS filed Critical Pharmaorigin AS
Publication of CA2579884A1 publication Critical patent/CA2579884A1/fr
Application granted granted Critical
Publication of CA2579884C publication Critical patent/CA2579884C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
CA2579884A 2004-09-10 2005-09-09 Procede pour traiter les saignements locaux tracheaux, bronchiques ou alveolaires ou l'hemoptysie Expired - Fee Related CA2579884C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60875904P 2004-09-10 2004-09-10
US60/608,759 2004-09-10
US62297704P 2004-10-28 2004-10-28
US60/622,977 2004-10-28
US69396905P 2005-06-24 2005-06-24
US60/693,969 2005-06-24
PCT/DK2005/000576 WO2006026998A1 (fr) 2004-09-10 2005-09-09 Procede pour traiter les saignements locaux tracheaux, bronchiques ou alveolaires ou l'hemoptysie

Publications (2)

Publication Number Publication Date
CA2579884A1 CA2579884A1 (fr) 2006-03-16
CA2579884C true CA2579884C (fr) 2013-12-31

Family

ID=35482229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2579884A Expired - Fee Related CA2579884C (fr) 2004-09-10 2005-09-09 Procede pour traiter les saignements locaux tracheaux, bronchiques ou alveolaires ou l'hemoptysie

Country Status (13)

Country Link
US (2) US8431535B2 (fr)
EP (1) EP1791555B1 (fr)
JP (2) JP2008512403A (fr)
KR (1) KR101241434B1 (fr)
AU (1) AU2005282065B2 (fr)
BR (1) BRPI0515163A (fr)
CA (1) CA2579884C (fr)
DK (1) DK1791555T3 (fr)
HK (1) HK1104970A1 (fr)
IL (1) IL181824A (fr)
MX (1) MX2007002903A (fr)
NO (1) NO20071824L (fr)
WO (1) WO2006026998A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005282065B2 (en) 2004-09-10 2013-02-07 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
CN101262879B (zh) * 2005-06-24 2013-04-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用活化的蛋白c
US20070225749A1 (en) 2006-02-03 2007-09-27 Martin Brian B Methods and devices for restoring blood flow within blocked vasculature
DK2004214T3 (da) 2006-03-16 2013-02-18 Stellaris Pharmaceuticals Aps Lokalbehandling med faktor VII
WO2010102307A1 (fr) 2009-03-06 2010-09-10 Lazarus Effect, Inc. Systèmes d'extraction et leur procédé d'utilisation
US20120141467A1 (en) * 2010-12-03 2012-06-07 Schneider Daniel J Ascorbic acid to treat chronic obstructive lung diseases and non-Hodgkin's lymphoma
US9301936B2 (en) 2013-07-08 2016-04-05 Imprimis Pharmaceuticals, Inc. Pharmaceutical formulations of tranexamic acid and their use
CN107405470A (zh) 2015-02-11 2017-11-28 柯惠有限合伙公司 带可扩张尖端的医疗装置和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920845A (en) * 1971-08-03 1975-11-18 Beecham Group Ltd 2-nitroindan-1,3-dione
US5096916A (en) * 1990-05-07 1992-03-17 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (copd) by inhalation of an imidazoline
US5427797A (en) * 1993-04-06 1995-06-27 Brigham And Women's Hospital Systemic effects of nitric oxide inhalation
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma
US5980865A (en) * 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
CA2278823A1 (fr) * 1997-01-29 1998-07-30 Joe M. Mccord Activateur du plasminogene utilise comme agent anti-inflammatoire
SI20413A (sl) * 1998-03-16 2001-06-30 Inhale Therapeutic Systems, Inc. Dajanje aerosoliziranega aktivnega sredstva
AU1161300A (en) * 1998-11-10 2000-05-29 Byk Gulden Lomberg Chemische Fabrik Gmbh Treatment set containing lungsurfactant compositions
EP1282439B1 (fr) * 2000-05-10 2005-11-30 Novo Nordisk Health Care AG COMPOSITION PHARMACEUTIQUE COMPRENANT UN FACTEUR VIIa ET UN INHIBITEUR DE TFPI
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
EP1446147A1 (fr) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Composition pharmaceutique comprenant des polypeptides du facteur vii et de l'acide tranexamique
CA2475097C (fr) * 2002-02-04 2012-05-08 Salpep Biotechnology Inc. Peptides anti-inflammatoires
CA2483102C (fr) * 2002-04-25 2013-06-18 The Scripps Research Institute Traitement et prevention d'affections pulmonaires
PT1499719E (pt) * 2002-04-30 2011-02-09 Bayer Healthcare Llc Variantes polipeptídicas do factor vii ou viia
EP1617799A2 (fr) * 2003-04-09 2006-01-25 Wyeth Traitement de l'hemophilie par inhalation de facteurs de coagulation
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US7404957B2 (en) * 2003-08-29 2008-07-29 Aerovance, Inc. Modified IL-4 mutein receptor antagonists
AU2005282065B2 (en) 2004-09-10 2013-02-07 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis

Also Published As

Publication number Publication date
JP2012092131A (ja) 2012-05-17
AU2005282065A1 (en) 2006-03-16
BRPI0515163A (pt) 2008-07-08
CA2579884A1 (fr) 2006-03-16
IL181824A0 (en) 2007-07-04
US20070258971A1 (en) 2007-11-08
MX2007002903A (es) 2007-07-11
AU2005282065B2 (en) 2013-02-07
KR101241434B1 (ko) 2013-03-12
KR20070067127A (ko) 2007-06-27
EP1791555B1 (fr) 2013-03-13
US7807639B2 (en) 2010-10-05
US20070060517A1 (en) 2007-03-15
IL181824A (en) 2012-05-31
EP1791555A1 (fr) 2007-06-06
DK1791555T3 (da) 2013-06-10
NO20071824L (no) 2007-04-10
WO2006026998A8 (fr) 2006-05-04
JP5537537B2 (ja) 2014-07-02
JP2008512403A (ja) 2008-04-24
HK1104970A1 (en) 2008-02-01
WO2006026998A1 (fr) 2006-03-16
US8431535B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
JP5537537B2 (ja) 局所的な気管、気管支、または肺胞の出血または喀血の治療方法
AU2006273696B2 (en) Airway administration of activated protein C in inflammatory conditions affecting the respiratory tract
KR20060126762A (ko) 외상의 말기 합병증을 치료하기 위한 인자 ⅴⅰⅰａ의 용도
RU2396086C2 (ru) Способы лечения трахеального, бронхиального или альвеолярного кровотечения или кровохарканья
ZA200702428B (en) Methods for treating local trachéal, bronchial or alveolar bleeding or hemoptysis
US20200024589A1 (en) Treatment for airway cast obstruction
MX2007016372A (es) Administracion a las vias respiratorias de la proteina c activada en condiciones inflamatorias que afectan el tracto respiratorio
MX2007016370A (en) Airway administration of tissue factor pathway inhibitor in inflammatory conditons affecting the respiratory tract

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180910